Classen has previously shown vaccines were responsible for the epidemic of type 1, insulin dependent, diabetes. The current paper provides evidence that common forms of type 1 diabetes and type 2 diabetes are actually opposing responses to vaccines. Upon receipt of vaccines some individuals develop substantial inflammation leading to autoimmune destruction of insulin secreting cells, type 1 diabetes. Other individuals produce increased cortisol, an immune suppressing hormone, to suppress the vaccine induced inflammation. The increased cortisol leads to obesity, type 2 diabetes and metabolic syndrome. Races which have high cortisol activity have increased risk of type 2 diabetes and metabolic syndrome.

In a previous publication in The Open Endocrinology Journal, Dr. Bart Classen showed a 50% reduction of type 2 diabetes occurred in Japanese children following the discontinuation of a single vaccine, a vaccine to prevent tuberculosis. This decline occurred at a time when there is an global epidemic of type 2 diabetes and metabolic syndrome. Japanese children secrete large amounts of cortisol following immunization compared to Caucasians and Japanese children also have a low risk of developing type 1 diabetes.

"The picture is becoming clear. Not only are vaccines causing an epidemic of autoimmunity including type 1 diabetes but they are causing an epidemic of metabolic syndrome as the immune system acts to suppress the inflammation and autoimmunity caused by the vaccines. Current data shows that vaccines are much more dangerous than the public is lead to believe and adequate testing has never been performed even in healthy subjects. The current practice of vaccinating diabetics as well as their close family members is a very risky practice," says Dr. Bart Classen.

Classen's research has become widely accepted. To view the published papers and to find out the latest information on the effects of vaccines on autoimmune diseases including insulin dependent diabetes visit the Vaccine Safety Web site http://www.vaccines.net/newpage11.htm

  Source: Classen Immunotherapies, Inc.